Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

samsha1 Feb. 4 at 3:15 AM

$SLS 🚀 $SLS – The AbbVie / $ABBV VEN Synergy The Strategy • GPS (WT-1 Vaccine): Phase 3 REGAL final OS data imminent (72/80 events). Goal = durable remission → functional dormancy • SLS009 (CDK9): Suppresses MCL-1 survival signaling → clean, mechanistic plug-and-play with VEN The Catalyst • True synergy: SLS009 shows activity in ASXL1-mutated AML (VEN-resistant population) • Seamless integration: Drops directly onto AZA/VEN backbone — no paradigm shift, no retraining Big Picture • GPS maintains disease control • SLS009 + VEN eliminates residual disease • Together = full-stack AML architecture Bottom Line • Purpose-built for AbbVie-scale expansion or acquisition 🧪🔥

0 · Reply

Moparian Feb. 3 at 10:54 PM

$SLS $ABBV $PFE

0 · Reply

Ro_Patel Feb. 3 at 10:44 PM

Medicare drug price negotiations to include treatments administered in doctors’ offices, including some for Type 2 diabetes, HIV, cancer & arthritis. These are drugs covered in Medicare Part B. Only retail medications covered by Part D were eligible for the talks during the previous two rounds of discussions. The negotiated prices for the 15 drugs chosen this year will take effect in 2028. About 1.8M beneficiaries used these medications b/n Nov 2024 & Oct 2025, and they accted for about $27B in Medicare Part B & D spending Note: 14 of the drugs, Medicare revs exposed to the negotiations represents only 0% to 3% of the companies’ worldwide 2027 sales. $GILD Biktarvy, a once-daily pill that treats HIV, draws significant sales from Medicare, representing around 8% of Gilead’s est'd global FY27 revs $LLY $ABBV $GSK $PFE

0 · Reply

Bayside1983 Feb. 3 at 10:05 PM

$ABBV $MRK $PFE $SLS

0 · Reply

cb5000calls Feb. 3 at 10:02 PM

$SLS 💣 Phase 3 AML trial PASSED interim efficacy + futility, now at 72/80 events with >2x historical OS — this is a de-risked, registration-ready cancer asset entering the endgame. 💥🧬📈 $PFE $MRK $ABBV all on deck right now.

0 · Reply

DonCorleone77 Feb. 3 at 7:35 PM

$LLY $ABBV $UBER $BSX $JCI Some notable companies reporting before tomorrow's open, with earnings consensus estimates: - Eli Lilly (LLY), consensus $6.93 - Abbvie (ABBV), consensus $2.65 - Uber (UBER), consensus 78c - Boston Scientific (BSX), consensus 78c - Johnson Controls (JCI), consensus 84c - Yum Brands (YUM), consensus $1.76 - GE Healthcare (GEHC), consensus $1.40 - Cognizant (CTSH), consensus $1.32 - Foxa (FOXA), consensus 52c - Equifax (EFX), consensus $2.05 - Fortive (FTV), consensus 84c

0 · Reply

eWhispers Feb. 3 at 6:35 PM

#earnings before the open on Wednesday, February 4, 2026 https://www.earningswhispers.com/calendar $UBER $LLY $NVO $ABBV $BSX

0 · Reply

Sunny3999 Feb. 3 at 4:16 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ABBV $BMY $MRK $SNY

0 · Reply

Sunny3999 Feb. 3 at 4:14 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ABBV $CELG $JNJ $PFE

0 · Reply

Strikerbiker Feb. 3 at 1:09 PM

$SLS Neither $PFE nor $MRK have any interest in $SLS. It‘s either $ABBV or Titanic.

1 · Reply

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:00 AM EST - 14 hours ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Jan 29, 2026, 10:30 PM EST - 5 days ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABVX CVLT FIX FTAI GKOS GMAB HLI

Jan 29, 2026, 10:10 AM EST - 5 days ago

10 Highest Rated Dividend Kings For Generations Of Income

ABM ABT ADM BDX BKH KMB KO

Jan 29, 2026, 8:00 AM EST - 5 days ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 28, 2026, 8:00 AM EST - 6 days ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 27, 2026, 4:52 PM EST - 7 days ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

Jan 27, 2026, 9:34 AM EST - 7 days ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Jan 25, 2026, 10:11 PM EST - 9 days ago

Best Dividend Kings: January 2026

ABM ABT ADM ADP AWR BDX BKH

$AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

Jan 16, 2026, 1:43 PM EST - 18 days ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:35 PM EST - 18 days ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

Jan 14, 2026, 5:45 PM EST - 20 days ago

AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:01 PM EST - 20 days ago

AbbVie plans to build out its presence in obesity market

Jan 13, 2026, 7:22 AM EST - 21 days ago

AbbVie reaches 3-year deal with White House to lower drug prices

Jan 13, 2026, 5:24 AM EST - 21 days ago

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

Jan 12, 2026, 7:03 PM EST - 22 days ago

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Jan 12, 2026, 6:57 PM EST - 22 days ago

Abbvie, US reach agreement to cut drug prices

Jan 12, 2026, 6:30 PM EST - 22 days ago

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

Jan 12, 2026, 7:39 AM EST - 22 days ago

AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:30 AM EST - 22 days ago

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

Jan 12, 2026, 6:00 AM EST - 22 days ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

WST

Jan 12, 2026, 6:00 AM EST - 22 days ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

WST

Jan 12, 2026, 5:12 AM EST - 22 days ago

Dividend Income: Lanny's November 2025 Summary

AFL CAT COF CVS CZNC EMR ETN

Jan 10, 2026, 9:30 AM EST - 24 days ago

MoneyShow's Best Investment Ideas For 2026: Part 1

ABR ACHR ARE ARES ARMN ASTS

Jan 8, 2026, 12:07 PM EST - 26 days ago

AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 7:38 AM EST - 26 days ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

RVMD

Jan 7, 2026, 2:58 PM EST - 27 days ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

RVMD

Jan 7, 2026, 2:48 PM EST - 27 days ago

AbbVie Near Deal for Revolution Medicines

RVMD

Jan 7, 2026, 8:00 AM EST - 27 days ago

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Jan 6, 2026, 11:43 AM EST - 4 weeks ago

What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 7:29 AM EST - 4 weeks ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ARGX NBIX

Jan 5, 2026, 8:00 AM EST - 4 weeks ago

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 4, 2026, 9:04 AM EST - 4 weeks ago

AbbVie: Rocky Near-Term, Positive Long-Term

Jan 3, 2026, 7:30 AM EST - 4 weeks ago

My Most Important Warning To Dividend Investors For 2026

AM ARES CNI CPT ENB EPD EXR

Jan 1, 2026, 10:24 PM EST - 4 weeks ago

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

Dec 31, 2025, 8:47 AM EST - 4 weeks ago

Best Dividend Aristocrats For January 2026

ABT ADM ADP AFL ALB AMCR AOS

Dec 28, 2025, 6:44 AM EST - 5 weeks ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH

Dec 19, 2025, 10:45 AM EST - 6 weeks ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO

Dec 17, 2025, 4:11 PM EST - 6 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

AMGN AZN BMY LLY NVS PFE

Dec 17, 2025, 2:17 PM EST - 6 weeks ago

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

MSFT NFLX TWLO

Dec 14, 2025, 11:30 PM EST - 7 weeks ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ALGT CGNX COHR EOLS INSP LTH MAT

Dec 10, 2025, 8:01 PM EST - 7 weeks ago

AbbVie: Unique Mix Of Growth And Value

Dec 8, 2025, 1:30 AM EST - 2 months ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

Dec 3, 2025, 4:53 PM EST - 2 months ago

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 8:15 AM EST - 2 months ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Dec 1, 2025, 5:55 AM EST - 2 months ago

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Nov 29, 2025, 8:02 AM EST - 2 months ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS

Nov 28, 2025, 7:01 AM EST - 2 months ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Nov 25, 2025, 9:30 AM EST - 2 months ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Nov 24, 2025, 8:00 AM EST - 2 months ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

samsha1 Feb. 4 at 3:15 AM

0 · Reply

Moparian Feb. 3 at 10:54 PM

$SLS $ABBV $PFE

0 · Reply

Ro_Patel Feb. 3 at 10:44 PM

0 · Reply

Bayside1983 Feb. 3 at 10:05 PM

$ABBV $MRK $PFE $SLS

0 · Reply

cb5000calls Feb. 3 at 10:02 PM

0 · Reply

DonCorleone77 Feb. 3 at 7:35 PM

0 · Reply

eWhispers Feb. 3 at 6:35 PM

#earnings before the open on Wednesday, February 4, 2026 https://www.earningswhispers.com/calendar $UBER $LLY $NVO $ABBV $BSX

0 · Reply

Sunny3999 Feb. 3 at 4:16 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ABBV $BMY $MRK $SNY

0 · Reply

Sunny3999 Feb. 3 at 4:14 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ABBV $CELG $JNJ $PFE

0 · Reply

Strikerbiker Feb. 3 at 1:09 PM

$SLS Neither $PFE nor $MRK have any interest in $SLS. It‘s either $ABBV or Titanic.

1 · Reply

samsha1 Feb. 3 at 6:55 AM

$SLS 🚀 $40+ Billy — ready to launch with $ABBV GPS, WT-1 Dormancy & the SLS009 “Lazarus Effect” in AZA/VEN 🧬 GPS (WT-1 vaccine) • Durable, antigen-specific immune pressure • Sustained dosing → immune memory • Result = functional dormancy • 5-year remission = often considered functional cure Now layer in SLS009 👇 🧟 The “Lazarus Effect” in AZA/VEN • Relapse on AZA/VEN = effectively palliative • Limited options, poor OS • Retreatment historically does not work Yet SLS009 appears to re-sensitize leukemia cells to AZA/VEN → A regimen that already failed can work again 🔁 Fail → re-sensitize → respond 🧠 Mechanism-driven reversal of resistance 🤝 AZA/VEN = $ABBV → partner-ready, launch-ready

0 · Reply

RonaldMeadows1095 Feb. 3 at 5:19 AM

$ABBV $BAC Income and scale

0 · Reply

koditrump Feb. 2 at 5:59 PM

$VERI $TWST $OLN $TGT $ABBV

0 · Reply

macrossluvsrobotech Feb. 2 at 5:22 PM

$LXRX A more perfect timeline could not have happened to us: 1. Jan 21st : FDA approved phase 3 Pilavapadin. 2. Jan 27-29 FIREST EVER: INAUGURAL ( meaning this will be a yearly event -quite historical in my view ) : Non-Opioid Pain Therapeutic Summit with $VRTX , $LLY $ABBV and other heavey hitters. 3. On the LAST DAY of the Summit, $LXRX responsibly tells of of their plans for liquidity. Then LATER on that same date, 13 hours later, after hours, we discover, exactly how much. A better timeline cannot exist. It just cannot.

0 · Reply

ZacksResearch Feb. 2 at 4:36 PM

$ABBV set for Q4 earnings — will Skyrizi & Rinvoq drive growth? 💊 🔹 Zacks Consensus Estimate for Q4 sales is $16.36B with EPS of $2.66 🔹 Skyrizi & Rinvoq sales projected at $4.91B & $2.39B, respectively 🔹 Humira's downward trend due to biosimilars continues Discover if ABBV is a long-term buy here 👉 https://www.zacks.com/stock/news/2827163/buy-abbvie-stock-before-q4-earnings-heres-what-to-know?cid=sm-stocktwits-2-2827163-body-31494&ADID=SYND_STOCKTWITS_TWEET_2_2827163_BODY_31494

0 · Reply

HydrogenH2 Feb. 2 at 3:36 PM

$ABBV Time to take some $$$

0 · Reply

ZacksResearch Feb. 2 at 3:36 PM

$ABBV ahead of Q4 earnings — growth engines vs. legacy pressure ⚖️ Skyrizi and Rinvoq are driving growth as Humira sales continue to slide, with shares trading at a discount to the industry heading into the quarter. What really matters before the print 👉 https://www.zacks.com/stock/news/2827163/buy-abbvie-stock-before-q4-earnings-heres-what-to-know?cid=sm-stocktwits-2-2827163-teaser-31482&ADID=SYND_STOCKTWITS_TWEET_2_2827163_TEASER_31482

0 · Reply

Czreri1 Feb. 2 at 3:27 PM

$ABBV same thing everyday pump in the first 30 and then sell off

0 · Reply

taxplanr Feb. 2 at 3:09 PM

Ivermectin treating Cancer has become well known but now it's treating Rheumatoid Arthritis $ABBV https://makisw.substack.com/p/ivermectin-fenbendazole-and-dmso?utm_source=post-email-title&publication_id=1385328&post_id=186452168&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

koditrump Feb. 2 at 1:08 PM

$ABBV $ABNB $ALGN $TSLA $WYNN Good Morning!! ⭐️⭐️⭐️⭐️⭐️⭐️⭐️⭐️⭐️⭐️

0 · Reply

HalfTrader Feb. 1 at 7:30 PM

$SLS $ATYR $MRK $ABBV

0 · Reply

dewmoore Feb. 1 at 1:19 PM

$SLS Happy February 1: The 'Godzilla' Math is officially locked. 🦖📈 Enrollment ended April '24. We are now at 22 MONTHS—officially beating the Phase 2 record. Since only 72 have died, the only way we fail is if the other 54 died over the weekend. Spoilers: THEY DIDN'T! The IDMC is in the hot seat this week or next week! Under the new Jan '26 FDA rules, if they see this 'overwhelming' efficacy (likely a 63:9 split), they MUST recommend stoppage. Ignoring this creates a massive legal liability & standard-of-care trap! The shorts are trapped in a 42M share hole with the 'Death Clock' stopped. This is our month. $SLS #AML #GPS #ShortSqueeze $ATYR $MRK $ABBV If you have NOT read this on REDDIT -- you should on your Sunday DD -- Let's make a lot of money gang!!!!!! https://www.reddit.com/r/TheRaceTo10Million/comments/1qsbg5l/sls_to_crown_hundreds_of_millionaires_in_february/

4 · Reply

Market Cap	394.14B
Revenue (ttm)	56.33B
Net Income (ttm)	4.28B
EPS (ttm)	N/A
PE Ratio	23.33
Forward PE	15.39
Profit Margin	7.59%
Debt to Equity Ratio	-26.45

Volume	8,158,500
Avg Vol	6,197,886
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	73%
Beta	0.36
Analysts	Strong Sell
Price Target	$245.80